Experiences of introducing new drugs for drug-resistant TB at the ALERT Hospital, Addis Ababa, Ethiopia, 2017-2019
© 2021 The Union..
BACKGROUND: Drug-resistant TB (DR-TB) remains a major public health concern. DR-TB patient data from ALERT (All Africa Leprosy, Tuberculosis and Rehabilitation Training Centre) Hospital, Addis Ababa, Ethiopia, who received bedaquiline (BDQ) and/or delamanid (DLM) containing regimens were analysed.
RESULTS: From 2017 to 2019, 51 DR-TB patients were enrolled. Of 33 patients, 31 (93.9%) had culture converted at 6 months. Of those with final outcomes, 77% (n = 10) were cured. Thirty (58.8%) developed adverse events, the most frequent of which were gastrointestinal disorders (70%), haematological disorders (16.7%) and QTc prolongation (16.7%). Twenty patients discontinued the offending drug permanently.
CONCLUSION: With close monitoring, introduction of new DR-TB regimens brought good early results, which encouraged wider programmatic implementation in Ethiopia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Public health action - 11(2021), 2 vom: 21. Juni, Seite 50-52 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tesema, E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ALERT Hospital |
|---|
| Anmerkungen: |
Date Revised 24.04.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.5588/pha.20.0065 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327063882 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327063882 | ||
| 003 | DE-627 | ||
| 005 | 20231225195940.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5588/pha.20.0065 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM327063882 | ||
| 035 | |a (NLM)34159060 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tesema, E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Experiences of introducing new drugs for drug-resistant TB at the ALERT Hospital, Addis Ababa, Ethiopia, 2017-2019 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 The Union. | ||
| 520 | |a BACKGROUND: Drug-resistant TB (DR-TB) remains a major public health concern. DR-TB patient data from ALERT (All Africa Leprosy, Tuberculosis and Rehabilitation Training Centre) Hospital, Addis Ababa, Ethiopia, who received bedaquiline (BDQ) and/or delamanid (DLM) containing regimens were analysed | ||
| 520 | |a RESULTS: From 2017 to 2019, 51 DR-TB patients were enrolled. Of 33 patients, 31 (93.9%) had culture converted at 6 months. Of those with final outcomes, 77% (n = 10) were cured. Thirty (58.8%) developed adverse events, the most frequent of which were gastrointestinal disorders (70%), haematological disorders (16.7%) and QTc prolongation (16.7%). Twenty patients discontinued the offending drug permanently | ||
| 520 | |a CONCLUSION: With close monitoring, introduction of new DR-TB regimens brought good early results, which encouraged wider programmatic implementation in Ethiopia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ALERT Hospital | |
| 650 | 4 | |a adverse event, treatment outcome | |
| 650 | 4 | |a multidrug-resistant-TB | |
| 700 | 1 | |a Wares, F |e verfasserin |4 aut | |
| 700 | 1 | |a Bedru, A |e verfasserin |4 aut | |
| 700 | 1 | |a Negeri, C |e verfasserin |4 aut | |
| 700 | 1 | |a Molla, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Gemechu, D |e verfasserin |4 aut | |
| 700 | 1 | |a Kassa, A |e verfasserin |4 aut | |
| 700 | 1 | |a Tsegaye, F |e verfasserin |4 aut | |
| 700 | 1 | |a Taye, L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Public health action |d 2011 |g 11(2021), 2 vom: 21. Juni, Seite 50-52 |w (DE-627)NLM235939358 |x 2220-8372 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:2 |g day:21 |g month:06 |g pages:50-52 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5588/pha.20.0065 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 2 |b 21 |c 06 |h 50-52 | ||